Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Tonix Pharmaceuticals Announces Publication Of Patent Application For Tnx 1500 Monoclonal Antibody Anti Cd40 Ligand In Development For Preventing And Treating Organ Transplant Rejection And Treating Autoimmune Conditions is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Tonix Pharmaceuticals Announces Publication of Positive Phase 3 RESILIENT Trial Data for TNX-102 SL in Fibromyalgia Management
Tonix Pharmaceuticals has announced the publication of its Phase 3 RESILIENT trial results for TNX-102 SL, a sublingual formulation of cyclobenzaprine for treating fibromyalgia. The data shows that ... Read More
Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine
The previously disclosed and now published RESILIENT data show that once-nightly TNX-102 SL achieved statistically significant improvement in the primary endpoint of reducing fibromyalgia pain versus ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus